Rafarma Pharmaceuticals, Inc. (OTC: RAFA) plans to announce the imminent launch of the most advanced pharmacovigilance and drug logistics solution for controlling and preventing medication stability risks. The company plans to begin a large-scale smart packaging testing program this summer in its international supply of drugs. Rafarma Pharmaceuticals believes that the developed technology is orders of magnitude surpasses the modern pharmaceutical industry achievements and ensures safe medicines transportation and storage.
The smart packaging technology is adapted to transport a wide range of medicines, including complex protein and live-cell drugs, tissues and organs for transplantation, radiopharmaceuticals and devices with short-lived isotopes. Smart packaging is a reusable modular design that allows to remotely control the quality of drugs during their transportation and storage. It provides a remote access interface to up-to-date information about the drugs placed in the package: location, integrity, drugs chemical balance state (actually the degree of suitability for use) and temperature profile in real-time. Product development has been carried out since 2018.
The device provides:
Data on physical quantities and chemical composition of transported medicinal substances
Data storage, at least 5000 (365/2*24) records date/time/temperature/pressure
Variable connection in the WiFi standard (802.11 n)
Support for data exchange protocol TCP/IP, MQTT
WEB interface
iBeacon functionality
The user will be able to view the EDR, which saves all information about transported medicines on the SD card and track stocks and reserves in clinics and warehouses, as well as promptly replenish them.
One of the key smart packaging topics is the prospect of its integration with the medical institutions’ electronic document management systems (EDMS). Rafarma Pharmaceuticals’ technology is a healthcare agent capable of making entries in the patient's medical record. As of 2019, the percentage of doctors in the United States using electronic medical records to some extent is 89.9% (2019 National Electronic Health Records Survey public use file national weighted estimates), and the figure is growing steadily from year to year. Along with it, a neural network that analyzes the results of using drugs for specific patients will be able to develop recommendations for similar cases.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. The pharmaceutical distribution industry saves the US healthcare system between $33 billion and $53 billion annually through investment in logistics solutions, supply chain improvements, and technological advancements. That is why the state continues to support the development of new medical logistics technologies and notes the industry prospects.
According to Fortune Business Insights, the global pharmacovigilance market will grow from $6.28 billion in 2021 to $14.85 billion in 2028, averaging +13.1% per year.
ABOUT RAFARMA PHARMACEUTICALS:
Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.
For more information, please visit https://www.noyarp.com
FORWARD-LOOKING STATEMENT:
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
CONTACTS:
RAFARMA PHARMACEUTICALS
(307) 429-2029
Source: Rafarma Pharmaceuticals, Inc.